PrecisionCHD™
Coronary Heart Disease Detection and Management
What is PrecisionCHD™?
PrecisionCHD™ is a clinical blood test, available by prescription only, that aids in the diagnosis of coronary heart disease (CHD) and identifies the specific molecular drivers of CHD for each patient. It evaluates a targeted panel of ten epigenetic and six genetic biomarkers associated with coronary heart disease. By applying artificial intelligence, the test predicts with high sensitivity whether a signal associated with coronary heart disease is detected.
PrecisionCHD™ allows providers to treat each patient as a category of one through a precise, individualized assessment of coronary heart disease. Using the lens of AI, it uncovers the molecular underpinnings that may precede symptoms and measurable physical changes, helping overcome the limitations of current tools and informing personalized care.
With re-testing, the DNA methylation biomarkers of PrecisionCHD™ have demonstrated to change in response to intervention. This test can detect both obstructive and non-obstructive disease in a non-invasive, radiation-free manner.
Test results include actionable insights on the impact of biomarkers on disease signal and associated pathways to help personalize care
Non-Invasive, No Radiation, No Fasting
Understanding the PrecisionCHD™ Clinical Report
Signal Not Detected
Signal Detected
The AI model was trained and validated to interpret the complex patterns and relationships between DNA methylation and single nucleotide polymorphisms to distinguish between individuals with and without a CHD diagnosis.
Signal Detected indicates the presence of methylation patterns previously observed in patients with a CHD diagnosis.
Signal Not Detected indicates that the patient’s methylation patterns are consistent with patients who were not diagnosed with CHD.
The ordering provider will receive an Actionable Clinical Intelligence report that outlines the patient-specific molecular drivers of disease. These insights explain the “why” behind the result, enabling more personalized care and better-informed decisions for preventing and managing coronary heart disease.
PrecisionCHD™ Is Intended for Patients Who:
Rx Only FSA/HSA Eligible
Are between 35 to 80 years old
Are presenting to be evaluated for coronary heart disease
Have not had a bone marrow transplant
No Radiation ● No Fasting ● Compatible with Telemedicine
Reveal the Molecular Drivers of Coronary Heart Disease With PrecisionCHD™
- Philibert R, Dogan TK, Knight S, Ahmad F, Lau S, Miles G, Knowlton KU, Dogan MV. Validation of an integrated genetic–epigenetic test for the assessment of coronary heart disease. J Am Heart Assoc. 2023;12:e030934. doi:10.1161/JAHA.123.030934